PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nedKargerHomeAlertsResources
 
Neuroepidemiology. 2008 October; 31(3): 139–149.
Published online 2008 August 21. doi:  10.1159/000151523
PMCID: PMC2683985
NIHMSID: NIHMS109218

Environmental Epidemiology of Essential Tremor

Abstract

Background

Essential tremor (ET) is one of the most common neurological disorders. Despite this, the disease mechanisms and etiology are not well understood. While susceptibility genotypes undoubtedly underlie many ET cases, no ET genes have been identified thus far. As with many other progressive, degenerative neurological disorders, it is likely that environmental factors contribute to the etiology of ET. Environmental epidemiology is the study in specific populations or communities of the effect on human health of physical, biologic and chemical factors in the external environment. The purpose of this article is to review current knowledge with regards to the environmental epidemiology of ET.

Results

As will be discussed, a series of preliminary case-control studies in recent years has begun to explore several candidate toxins/exposures, including harmane (1-methyl-9H-pyrido[3,4-b]indole), lead and agricultural exposures/pesticides.

Conclusions

While several initial results are promising, as will be discussed, additional studies are needed to more definitively establish whether these exposures are associated with ET and if they are of etiological importance.

Key Words: Essential tremor, Environmental epidemiology, Etiology, Toxin, Harmane, Lead, Pesticides

Introduction to Essential Tremor as a Clinical Entity

Essential tremor (ET) is a chronic, progressive, degenerative brain disease whose most recognizable feature is a 4- to 12-Hz kinetic tremor (that is, tremor occurring during volitional movement) of the arms [1]. The tremor may range in severity from mild and functionally unimportant to severe and disabling [2,3,4,5,6]. Aside from arm tremor, head and voice tremors may occur as well [1, 7]. The clinical features can include a number of other types of tremor, other motor manifestations and nonmotor features. In terms of other types of tremor, many patients also have intention tremor (that is, tremor while approaching a target) and rest tremor occurs in some as well [8,9,10]. Other motor manifestations have been documented repeatedly. Thus, changes in tandem gait and balance can occur in some ET patients; this gait has been described as ataxic [11, 12]. ET patients with intention tremor have other cerebellar signs such as disdiadochokinesia [13]. Mild oculomotor abnormalities have been documented in ET as well [14]. The presence of a variety of nonmotor features, including specific personality traits [15, 16], anxiety [17], depressive symptoms [4,18,19,20] and social phobia [21],is gaining wider recognition [22, 23]. Mild cognitive changes (especially executive dysfunction) have been documented in 6 studies [24,25,26,27,28,29]and increased odds and risk of dementia in 2 [30, 31]. Hence, the view of ET that is emerging from clinical studies is that this heterogeneous condition is probably a family of diseases whose central defining feature is action tremor of the hands but in which there is considerable clinical heterogeneity [1, 7, 32].

Epidemiology of ET

There have been more than 20 studies of the prevalence of ET [33, 34]. Estimates of the crude prevalence of this disorder have varied considerably from study to study, with a number of methodological considerations (for example, use of screening questionnaires in order to select participants for tremor examinations) contributing greatly to this variability. However, in a population-based study in Turkey, in which all individuals were examined by a study neurologist, the prevalence of ET was 4.0% among individuals aged 40 years and older and 6.3% among individuals ≥60 years of age [33]. In another population-based study in Finland that used a similar methodology [35], the prevalence was 5.6% in individuals aged 40 years and older and 9.0% among individuals ≥60 years of age. Although an age-associated increase in prevalence is a consistent finding across studies [34], and prevalence is highest after the sixth decade [33, 34], the disorder can on occasion begin in childhood [36, 37], with many of these young-onset cases being familial [3, 38, 39]. While prevalence appears to be similar in men and women, it has been reported to be marginally higher in Caucasians than African-Americans [40,41,42].

Two studies have provided estimates of the incidence of ET. In one study [43], which used a records linkage system to capture all health encounters with individuals with ET, the age- and sex-adjusted incidence was 23.7 per 100,000 White US population. Another study [44], which sampled ET cases directly from the population in the Madrid region, reported an incidence (age ≥65 years) of 616 per 100,000, which was substantially higher than that of the prior study.

Despite the fact that it is a progressive disorder [45,46,47], there are few longitudinal data in patients with ET. In one study [48], 44 patients were followed prospectively for 4 years and accelerometric data demonstrated an approximately 7% increase in arm tremor amplitude per year, while in another clinical study, an approximately 12% annual change was reported in clinical tremor ratings [49]. These studies confirm the clinical anecdotal sense that the action tremor of ET worsens over time.

A wealth of clinical data centers on the apparent links between ET and Parkinson's disease (PD) [50,51,52,53,54,55,56]. The development of PD has often been described in ET patients [50, 56, 57]. In recent studies, ET patients were 2–4 times more likely to develop PD (that is, ET plus PD) when compared to persons without ET [57, 58]. ET-like action tremor is more common in PD families than control families [52], further supporting the links between ET and PD, and postmortem studies have now shown that a subset of ET patients has brainstem (mainly in the locus ceruleus) Lewy bodies [59,60,61].

Mild cognitive changes (especially executive dysfunction) have been documented in 6 studies of ET, several of which had a case-control design [24,25,26,27,28,29]. One study further showed an increased odds of prevalent dementia and then an increased risk of incident dementia in older-onset ET cases when compared with age-matched controls [30, 31].

Studies of mortality are conflicting. While the traditional belief had been that ET was not associated with mortality, there were few data and these data were retrospective [43]. Recent data from a prospective, population-based study in Spain, showed a 45% increased risk of mortality in ET, suggesting that the disease may be associated both with increased morbidity and mortality [62].

A number of factors may influence the clinical expression of ET. First, there seems to be an association between age of onset and rate of clinical progression, with older-onset cases having a faster rate of progression [46]. Furthermore, the odds of developing head tremor are markedly higher in women with ET than men with ET [63,64,65].

Underlying Disease Mechanisms

It is important to consider the underlying pathological anatomy and mechanistic basis of a disease when investigating how and where a putative etiological agent like a toxin enters the brain and then how it produces pathogenic effects. The underlying anatomic pathology of ET has been elusive, although recent postmortem studies have begun to reveal some of the basic underlying degenerative brain changes in patients with this disease. These studies demonstrate 2 different pathologically defined subgroups of ET patients: the majority has degenerative changes [Purkinje cell loss and torpedoes (swellings of the Purkinje cell axon)] in the cerebellum (cerebellar ET), while a smaller number has brainstem Lewy bodies (mainly in the locus ceruleus) with a relatively preserved cerebellum (Lewy body variant of ET) [59, 66, 67]. The presence of Lewy bodies in some ET cases is intriguing and, as noted above, may explain the apparent clinical links between ET and PD. From an epidemiological perspective, this raises the possibility that the same set of environmental risk factors might trigger both diseases.

Etiology of ET

ET is often considered to be largely a genetic disorder [68,69,70,71,72,73,74]. There are numerous published examples of families in which the proband and multiple relatives have ET [68,70,71,72,74,75,76,77,78,79] and in which the pattern of inheritance is most consistent with an autosomal dominant model. In 1997, linkage was demonstrated to a region on chromosome 2p22-25 in several American families [70] and, in that same year, to chromosome 3q13 in 16 Icelandic families [74]. Since then, one other study has demonstrated linkage to a region on chromosome 6p23 in several North American families [73]. Other studies have failed to demonstrate linkage to these 3 regions, indicating further genetic heterogeneity [69, 72, 80, 81]. Studies have not progressed further and no ET genes have been identified so far [69, 70, 73, 74]. A number of studies have also explored the role of genetic polymorphisms in ET [77,82,83,84,85,86,87,88,89,90], with single reports of associations between ET and polymorphisms in the following genes: glutathione-S-transferase P1 (involved in metabolism of carcinogens) [84], δ-amino-levulinic acid dehydrogenase (involved in lead kinetics) [86], methylenetetrahydrofolate reductase (involved in folate- and vitamin B12-dependent homocysteine metabolism) [83] and CYP2C19 (possibly related to primidone metabolism) [85].

Although widely considered to have a large genetic component, it is likely that environmental factors contribute to the etiology of ET as well. First, it is commonly stated in the literature that 50% or more of ET cases have a genetic basis, although some estimates are as low as 17% [91]. In the only familial aggregation study of ET [92], 55% of ET cases had no affected first- or second-degree relatives, despite examination of 4.5 relatives per case, on average. This was consistent with data from other series, among whom the majority (>50%) of ET cases do not report affected relatives [20, 91,93,94,95,96,97]. Second, in twin studies [98, 99] concordance in monozygotic twins was <100% (that is, it was 60% in one study and 63% in another). Third, the existence of intrafamilial differences in age of onset and severity of tremor [100, 101] also suggests that environmental (or perhaps other genetic) factors may be serving as modifiers of an underlying susceptibility genotype. Fourth, temporal trends in disease incidence can support the notion that environmental factors may be contributing to the etiology of ET. A temporal trend in the annual incidence of ET was reported in Rochester, Minnesota [43], where the annual age-adjusted incidence per 100,000 rose from 5.8 in the period from 1935 to 1949, to 15.8 in the period from 1950 to 1964 and 23.5 from 1965 to 1975. These data, however, should be approached with caution as this trend could also be the result of increased recognition and diagnosis of the disorder rather than a true rise in disease incidence.

Environmental factors are also thought to play a substantial role in other neurological disorders (PD, Alzheimer's disease, amyotrophic lateral sclerosis) [102,103,104,105,106,107,108,109,110,111,112,113], so that it is not inconceivable that they could play a role in ET. Using the commonly cited value of 50% for the percentage of cases that occur on a familial basis [91, 114], and given its population prevalence of 4.0% after age 39 years [33], this then suggests that approximately 2.0% of the population aged ≥40 years has a nonfamilial form of ET [33]. Despite the apparent extent of the problem, the environmental correlates for this tremor are just beginning to be explored.

Possible Environmental Toxins in ET

Harmane (1-methyl-9H-pyrido[3,4-b]indole)

In the selection of possible toxic causes of ET for investigation, the β-carboline alkaloids are a reasonable choice. They are a group of naturally occurring chemicals that include harmane, norharman, harmine, harmaline and others [115,116,117]. β-Carboline alkaloids are a type of heterocyclic amine; structurally, they are comprised of a combination of 5- and 6-ringed (that is, cyclic) carbon structures, which contain an amine group [118]. There is a structural similarity with the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), which forms the basis for one of the main toxin-induced animal models for PD [119, 120]. Like MPTP, β-carboline alkaloids are highly neurotoxic, and it has been known for approximately 100 years that administration of β-carboline alkaloids to a wide variety of laboratory animals produces an intense and generalized action tremor resembling ET [121]. β-Carboline alkaloid administration is currently the main animal model for ET and it has been proposed that new pharmacotherapies be tested using exposed animals [122,123,124,125,126]. The β-carboline alkaloid tremor shares many features with ET, including its principal clinical features (such as tremor frequency), drug response characteristics (responsive to benzodiazepines, ethanol and barbiturates) [126,127,128,129,130,131] and underlying brain changes (changes in the cerebellum, including Purkinje cell loss, have now been documented in ET [67,132,133,134,135,136,137]; similarly, β-carboline alkaloids produce toxic damage with significant loss of cerebellar Purkinje cells) [121, 126, 127,138,139,140,141]. Among human volunteers exposed to intravenously administered harmine, neurological effects include an acute, coarse tremor [142, 143].

Harmane (1-methyl-9H-pyrido[3,4-b]indole) is among the more potent tremor-producing β-carboline alkaloids [115]. Harmane itself is also very lipid soluble [116] and broadly distributed within the rat brain [144,145,146]. Brain concentrations are several fold higher than those in the blood [116, 145].

While β-carboline alkaloids are produced endogenously [147, 148], one study estimated that dietary sources were 50 times greater than these endogenous sources [149]. β-Carboline alkaloids are found in particularly high nanogram/gram concentrations in muscle foods (beef, chicken and pork) and cooking leads to furthermore increased concentrations [150,151,152,153]. Indeed, the formation of β-carboline alkaloids in cooked meat is a function of cooking temperature and time, with β-carboline alkaloid concentrations increasing most rapidly with time at higher temperatures [154, 155]. Pan frying and grill/barbequing produce the highest concentrations of β-carboline alkaloids. In addition to their high concentration in meat, β-carboline alkaloids are also present in varying concentrations in plant-derived foods/substances, including coffee, ethanol and tobacco [156].

In 2002, Louis et al. [157] demonstrated that blood harmane concentration was elevated in 100 ET patients at the Neurological Institute of New York compared to 100 matched control subjects (median blood harmane: 5.21 g−10/ml in cases vs. 2.28 g−10/ml in controls, p = 0.005). In analyses that adjusted for age and other confounders, there was a robust association between log blood harmane concentration and ET diagnosis: odds ratio (OR)ET vs. control = 1.80, 95% confidence interval (CI) = 1.10–2.93, p = 0.02 (that is, each 1 g−10/ml increase in blood harmane concentration was associated with an 80% increased odds of ET) [157]. With continued enrollment from the years 2002–2007, a larger replicate sample of 150 ET cases and 135 matched controls was assembled [158]. While overall concentrations were lower in this sample, the case-control difference persisted (median blood harmane: 2.61 g−10/ml in cases vs. 1.82 g−10/ml in controls, p = 0.016) [158].

Using magnetic resonance spectroscopic imaging, Louis et al. [159] also demonstrated a strong inverse correlation between cerebellar N-acetyl aspartate to creatine ratio (a marker of neuronal damage) and blood harmane concentrations (p = 0.009, adjusting for age and gender) in a small study of 12 ET cases. This correlation was not found in other brain regions (such as thalamus and basal ganglia) or with other neurotoxins (such as lead) [159]. These findings suggest that increased blood harmane concentration could be associated with greater cerebellar neuronal damage, consistent with the animal study data that harmane and other β-carboline alkaloids produce cerebellar damage [121, 126, 127,138,139,140,141]. Studies of human postmortem tissue are needed to further test this association.

As noted above, harmane is found in high concentrations in cooked meats. In an initial study in 2005, Louis et al. [160] compared animal protein consumption in 106 ET cases versus 161 controls. Total daily animal protein consumption was similar in cases and controls (50.2 ± 19.6 vs. 49.4 ± 19.1 g/day, p = 0.74). However, the study used a standardized food frequency questionnaire [161]. In a follow-up study [162], a more detailed meat consumption questionnaire was used. In that study, total meat consumption was greater in men with ET versus men without ET (135.3 ± 71.1 vs. 110.6 ± 80.4 g/day, p = 0.03) but not in women with versus without ET (80.6 ± 50.0 vs. 79.3 ± 51.0 g/day, p = 0.76). Male ET cases had a higher odds of being in the highest versus lowest quartile of current meat consumption than did male controls (unadjusted OR = 9.29, 95% CI = 2.29–37.64, p = 0.002; adjusted OR = 21.36, 95% CI = 3.52–129.51, p = 0.001). That study provided preliminary evidence of a dietary difference between males with ET versus males without ET [162], raising the question whether this possible dietary difference, through harmane consumption, could be linked with ET.

The study of harmane and its association with ET has been intriguing, yet the links need to be further developed and convincingly established. There are a number of basic unanswered questions. First, although elevated harmane concentrations have been observed in ET cases in blood, it is not known whether brain concentrations of this neurotoxin are elevated in ET. Second, current data were derived from a single study of ET cases mainly from a tertiary referral center and they need to be reproduced elsewhere. Third, one small study found elevated blood harmane concentrations in patients with PD [163], which raises the question as to whether elevated blood harmane is specifically linked with ET or if it is merely a more general, global marker of neurological illness. Addressing these basic questions would further delineate the possible association between ET and this neurotoxin. Additional studies would also be required to demonstrate that the exposure preceded the disease and was of etiological importance.

Lead

Human beings may be exposed to organic and inorganic forms of lead through a number of occupational and nonoccupational sources [164, 165]. In both laboratory animals and human beings, lead exposure may result in an acute or chronic progressive disorder in which action tremor is a prominent feature [164,166,167,168,169,170]. Lead exposure produces a destructive cerebellar pathology. Thus, rat pups fed a diet containing 4% lead acetate demonstrated changes in Purkinje cell morphology [171]. Perinatal exposure to inorganic lead results in degenerative changes in rabbit Purkinje cells [172]. Postmortem examination of humans with chronic organic lead exposure revealed marked destruction of Purkinje cells [169]. This is of particular interest given the observation, noted above, of cerebellar pathology in ET [67,132,133,134,135,136,137].

Preliminary evidence suggests that there may be an association between lead exposure and ET. In an initial study at a tertiary referral center in New York [173], blood lead concentrations were measured and a lifetime occupational history was assessed in 100 ET patients and 143 matched controls. Although blood lead concentrations were low in absolute terms, these concentrations were higher in ET patients than in controls (median: 2.7 vs. 2.3 mg/dl; p = 0.038). In an adjusted logistic regression model, blood lead concentration was associated with ET diagnosis: OR = 1.19; 95% CI = 1.03–1.37, p = 0.02 (that is, each 1 mg/dl increase in blood lead concentration was associated with a 19% increased odds of ET). Whether the observed association was due to increased exposure to lead or a difference in lead kinetics/metabolism was not investigated. The prevalence of a history of lifetime occupational lead exposure was similar in ET patients and controls. In a second study [86], the mechanism was explored further. The δ-amino-levulinic acid dehydratase (ALAD) gene codes for ALAD, the principal enzyme involved in lead kinetics. Carriers of the ALAD-2 allele may be more susceptible to lead toxicity. Eighteen (28.6%) of sixty-three ET cases versus 17 (16.8%) of 101 controls had an ALAD-2 allele (OR = 1.98, 95% CI = 0.9–4.2, p = 0.077) and there was an interaction between blood lead concentration and ALAD allele status; the odds of ET were greatly elevated (OR = 80.3; 95% CI = 3.1–2,096.4, p = 0.008) in individuals with both an ALAD-2 allele and an elevated blood lead concentration. Blood lead concentration was later evaluated in a second study of ET patients at a hospital in Turkey [174]. In that study, the median blood lead concentration was 2.7 mg/dl in 105 ET cases versus 1.5 mg/dl in 105 controls (p < 0.001). In a logistic regression model, blood lead concentration was associated with ET diagnosis: OR = 4.0; 95% CI = 2.5–6.4, p < 0.001 (that is, each 1 mg/dl increase in blood lead concentration was associated with a 4-fold increased odds of ET). These data replicated those of the previous study in New York.

The possible association of lead exposure with ET is intriguing, yet it needs to be further explored with additional replicate samples, preferably from population-based studies. Furthermore, bone lead concentration, which is a more valid measure of chronic lead exposure than blood lead, needs to be assessed in ET cases and controls.

Pesticides

There is a sizable literature on the association between pesticide exposure and PD [104, 107, 108]. As a class of chemicals, pesticides can produce tremor (including action tremor), and organochlorine pesticides (OCPs) are particularly tremorogenic in animals and humans [175,176,177,178]. The literature on pesticide exposure and ET, however, is limited to few studies [177]. In a study in New York [177], 6 serum OCP concentrations and lifetime occupational histories were assessed in 136 ET cases ascertained from a tertiary referral center and 144 matched control subjects. The 6 serum OCP concentrations were similar in cases and controls. Three (2.2%) ET cases versus 9 (6.3%) controls had past occupational exposure to OCPs. This apparent lack of a case-control difference in self-reported exposure to pesticides was confirmed in a second study in Spain of 142 ET patients and 284 controls [179] as well as a third study in Singapore of 79 ET patients and 100 controls, which demonstrated no difference in terms of self-reported pesticide exposure [180]. Exposure histories in each study, however, were brief. These studies represent a beginning and additional studies of ET are needed to assess a wider array of pesticides in more detail, using occupational histories, assessments of residential exposures and biological measures.

Other Exposures

A small number of studies have examined other potential exposures and their relation to ET. One study at a tertiary referral center in New York examined whether occupational exposures to manganese or organic solvents were associated with ET, but did not find an association [181]. This lack of association was confirmed in a second study in Spain of 142 ET patients and 284 controls [179]. In a study in Italy of 27 dental technicians (mean age 49.1 years, no controls), 4 (14.8%) had mild postural tremor [182], raising the issue of occupational toxin exposure, but these results are difficult to interpret given the high prevalence of postural tremor in the population [183]. While the issue of pesticide exposure was discussed above, 2 studies have raised questions about the more general association between agricultural exposures and ET. A small door-to-door survey in Italy that included 28 ET cases and 28 controls noted that the odds for habitual exposure to agricultural chemicals and domestic animals were 2.5 and 2.7 times higher in ET cases, respectively (results not significant) [95];each of these factors has been reported to be associated with PD [184]. A study of 142 clinic patients and 282 controls in Spain similarly reported that exposure to agricultural work was associated with ET (for agricultural exposure, OR = 25.4, 95% CI = 1.43–4.51, p = 0.002); however, reported family history was more strongly associated with ET in that study (OR = 34.2, 95% CI = 18.1–64.7, p < 0.001) [179]. Additional studies are needed.

Ethanol

Patients with ET may use ethanol to temporarily lessen the amplitude of their tremor [185, 186], although quantitative studies on relative ethanol consumption in ET cases versus controls have yielded mixed results [187]. The generally accepted causal pathway is that having ET might lead to increased ethanol consumption rather than the converse. Given this model, ethanol would not be considered a risk factor for ET. However, ethanol is a known cerebellar toxin, resulting in profound Purkinje cell loss [188]. Given the emerging links between ET and cerebellar pathology [66], this raises the question as to whether ethanol consumption might be associated with increased risk of incident ET, earlier age of onset of incident ET or more rapid rate of progression of prevalent ET. These issues have not been studied.

Possible Protective Exposures (Cigarettes)

Numerous studies have demonstrated an association between cigarette smoking and lower risk of PD [189, 190]. Three studies, all in Spain, have examined smoking habits in ET cases compared to controls [179, 191, 192]. In the first of these [179], the proportion of ET clinic patients and controls who smoked was similar, yet the number of cigarette pack years was marginally lower in cases than in controls. The second of these studies was a population-based study in Madrid [191]. In that study, ever smokers were approximately one half as likely to have prevalent ET when compared with never smokers (OR = 0.58, 95% CI = 0.40–0.84, p = 0.004) and ever smokers in the highest cigarette pack year tertile were one third as likely to have ET when compared with never smokers (adjusted OR = 0.39, 95% CI = 0.22–0.69, p = 0.001). Finally, in the same study, the association between baseline smoking and incident ET was later examined [192]. Five (6.5%) of seventy-seven incident ET cases had been smokers at baseline compared with 392 (12.0%) of 3,271 controls (p = 0.14). Baseline pack years were lower in incident ET cases than controls (9.2 ± 17.7 vs. 15.7 ± 28.4, p = 0.002). In Cox proportional hazards models, highest baseline pack year tertile was associated with lower risk of incident ET; those in the highest baseline pack year tertile were one third as likely to develop incident ET when compared to nonsmokers (adjusted relative risk = 0.29, 95% CI = 0.09–0.90, p = 0.03).

The biological basis for an association between cigarette smoking and possible lower risk of incident ET is not clear. Nicotine has been the focus of this effect for several reasons. First, nicotine is known to protect against the degenerative effects of toxic insults in different experimental systems [193,194,195]. Nicotine pretreatment consistently reduces the detrimental effects of excitotoxin exposure in cultured cells [193,194,195], including neurotoxin-induced degeneration of nigral dopamine-containing neurons [196]. Finally, in rats and mice, nicotine can protect against Parkinsonism-inducing neurotoxins like MPTP and methamphetamine [197].

While early epidemiological studies appear to show an inverse dose-dependent association between smoking and the risk of ET, additional prospective studies are needed to further explore the possible protective effects of smoking on risk of ET. Even if such studies were to be confirmatory, given the other adverse health effects of smoking, this activity should not be considered a prudent strategy for reducing the risk of ET.

Caveats

ET is a common and very widespread disorder whose etiology is likely to be the result of a complex variety of factors. A particular neurotoxin is likely to play an etiological role only in subsets of ET cases, which makes it more difficult to explore and establish such associations when one has no understanding of and has not yet identified those subsets.

Furthermore, while one scenario is that a neurotoxin/environmental factor is by itself sufficient to result in a neurological disease, another possibility is that the toxin merely increases the propensity for developing the disorder. For example, a toxin might result in a set of biological changes in the cerebellum (such as Purkinje cell loss), which then increase the exposed individual's sensitivity to the toxic effects of a second event.

Summary

While ET is widely considered to have a large genetic component [68,69,70,71,72,73,74], it is likely that environmental factors contribute to the etiology of ET as well. Such factors are similarly thought to play a substantial role in other progressive, degenerative neurological disorders [102,103,104,105,106,107,108,109,110,111,112,113]. Work over recent years has explored a number of exposures, including harmane, lead and agricultural exposures/pesticides in preliminary case-control studies, but further work is needed to more fully establish whether these toxins are risk factors for ET. Initial work also suggests that cigarette smoking might be protective of ET.

By some estimates, 2.0% of the population aged ≥40 years has a nonfamilial form of ET. Despite these high numbers, the environmental correlates for this tremor are just beginning to be explored.

Acknowledgements

R01 NS039422 from National Institutes of Health (Bethesda, Md., USA).

References

1. Louis ED. Clinical practice: essential tremor. New Engl J Med. 2001;345:887–891. [PubMed]
2. Busenbark KL, Nash J, Nash S, Hubble JP, Koller WC. Is essential tremor benign? Neurology. 1991;41:1982–1983. [PubMed]
3. Bain PG, Findley LJ, Thompson PD, Gresty MA, Rothwell JC, Harding AE, Marsden CD. A study of hereditary essential tremor. Brain. 1994;117:805–824. [PubMed]
4. Louis ED, Barnes L, Albert SM, Cote L, Schneier FR, Pullman SL, Yu Q. Correlates of functional disability in essential tremor. Mov Disord. 2001;16:914–920. [PubMed]
5. Koller W, Biary N, Cone S. Disability in essential tremor: effect of treatment. Neurology. 1986;36:1001–1004. [PubMed]
6. Rautakorpi I: Essential tremor: an epidemiological, clinical and genetic study; thesis, Turku, 1978.
7. Louis ED. Essential tremor. Lancet Neurol. 2005;4:100–110. [PubMed]
8. Cohen O, Pullman S, Jurewicz E, Watner D, Louis ED. Rest tremor in patients with essential tremor: prevalence, clinical correlates, and electrophysiologic characteristics. Arch Neurol. 2003;60:405–410. [PubMed]
9. Leegwater-Kim J, Louis ED, Pullman SL, Floyd AG, Borden S, Moskowitz CB, Honig LS. Intention tremor of the head in patients with essential tremor. Mov Disord. 2006;21:2001–2005. [PubMed]
10. Deuschl G, Wenzelburger R, Loffler K, Raethjen J, Stolze H. Essential tremor and cerebellar dysfunction clinical and kinematic analysis of intention tremor. Brain. 2000;123:1568–1580. [PubMed]
11. Singer C, Sanchez-Ramos J, Weiner WJ. Gait abnormality in essential tremor. Mov Disord. 1994;9:193–196. [PubMed]
12. Stolze H, Petersen G, Raethjen J, Wenzelburger R, Deuschl G. The gait disorder of advanced essential tremor. Brain. 2001;124:2278–2286. [PubMed]
13. Koster B, Deuschl G, Lauk M, Timmer J, Guschlbauer B, Lucking CH. Essential tremor and cerebellar dysfunction: abnormal ballistic movements. J Neurol Neurosurg Psychiatry. 2002;73:400–405. [PMC free article] [PubMed]
14. Helmchen C, Hagenow A, Miesner J, Sprenger A, Rambold H, Wenzelburger R, Heide W, Deuschl G. Eye movement abnormalities in essential tremor may indicate cerebellar dysfunction. Brain. 2003;126:1319–1332. [PubMed]
15. Chatterjee A, Jurewicz EC, Applegate LM, Louis ED. Personality in essential tremor: further evidence of non-motor manifestations of the disease. J Neurol Neurosurg Psychiatry. 2004;75:958–961. [PMC free article] [PubMed]
16. Lorenz D, Schwieger D, Moises H, Deuschl G. Quality of life and personality in essential tremor patients. Mov Disord. 2006;21:1114–1118. [PubMed]
17. Tan EK, Fook-Chong S, Lum SY, Gabriel C, Koh KK, Prakash KM, Louis ED. Non-motor manifestations in essential tremor: use of a validated instrument to evaluate a wide spectrum of symptoms. Parkinsonism Relat Disord. 2005;11:375–380. [PubMed]
18. Miller KM, Okun MS, Fernandez HF, Jacobson CE, 46th, Rodriguez RL, Bowers D. Depression symptoms in movement disorders: comparing Parkinson's disease, dystonia, and essential tremor. Mov Disord. 2007;22:666–672. [PubMed]
19. Louis ED, Benito-Leon J, Bermejo-Pareja F. Self-reported depression and anti-depressant medication use in essential tremor: cross-sectional and prospective analyses in a population-based study. Eur J Neurol. 2007;14:1138–1146. [PubMed]
20. Dogu O, Louis ED, Sevim S, Kaleagasi H, Aral M. Clinical characteristics of essential tremor in mersin, turkey – a population-based door-to-door study. J Neurol. 2005;252:570–574. [PubMed]
21. Schneier FR, Barnes LF, Albert SM, Louis ED. Characteristics of social phobia among persons with essential tremor. J Clin Psychiatry. 2001;62:367–372. [PubMed]
22. Louis ED. Behavioral symptoms associated with essential tremor. Adv Neurol. 2005;96:284–290. [PubMed]
23. Findley LJ. Expanding clinical dimensions of essential tremor. J Neurol Neurosurg Psychiatry. 2004;75:948–949. [PMC free article] [PubMed]
24. Lombardi WJ, Woolston DJ, Roberts JW, Gross RE. Cognitive deficits in patients with essential tremor. Neurology. 2001;57:785–790. [PubMed]
25. Lacritz LH, Dewey R, Jr, Giller C, Cullum CM. Cognitive functioning in individuals with ‘benign’ essential tremor. J Int Neuropsychol Soc. 2002;8:125–129. [PubMed]
26. Duane DD, Vermilion KJ. Cognitive deficits in patients with essential tremor. Neurology. 2002;58:1706. author reply 1706. [PubMed]
27. Vermilion K, Stone A, Duane D. Cognition and affect in idiopathic essential tremor. Mov Disord. 2001:16.
28. Gasparini M, Bonifati V, Fabrizio E, Fabbrini G, Brusa L, Lenzi GL, Meco G. Frontal lobe dysfunction in essential tremor: a preliminary study. J Neurol. 2001;248:399–402. [PubMed]
29. Benito-Leon J, Louis ED, Bermejo-Pareja F. Population-based case-control study of cognitive function in essential tremor. Neurology. 2006;66:69–74. [PubMed]
30. Benito-Leon J, Louis ED, Bermejo-Pareja F. Elderly-onset essential tremor is associated with dementia. Neurology. 2006;66:1500–1505. [PubMed]
31. Bermejo-Pareja F, Louis ED, Benito-Leon J. Risk of incident dementia in essential tremor: a population-based study. Mov Disord. 2007 [PubMed]
32. Benito-Leon J, Louis ED. Essential tremor: emerging views of a common disorder. Nat Clin Pract Neurol. 2006;2:666–678. [PubMed]
33. Dogu O, Sevim S, Camdeviren H, Sasmaz T, Bugdayci R, Aral M, Kaleagasi H, Un S, Louis ED. Prevalence of essential tremor: door-to-door neurologic exams in Mersin province, Turkey. Neurology. 2003;61:1804–1806. [PubMed]
34. Louis ED, Ottman R, Hauser WA. How common is the most common adult movement disorder? Estimates of the prevalence of essential tremor throughout the world. Mov Disord. 1998;13:5–10. [PubMed]
35. Rautakorpi I, Takala J, Marttila RJ, Sievers K, Rinne UK. Essential tremor in a finnish population. Acta Neurol Scand. 1982;66:58–67. [PubMed]
36. Louis ED, Dure LSt, Pullman S. Essential tremor in childhood: a series of nineteen cases. Mov Disord. 2001;16:921–923. [PubMed]
37. Louis ED, Fernandez-Alvarez E, Dure LS, 4th, Frucht S, Ford B. Association between male gender and pediatric essential tremor. Mov Disord. 2005;20:904–906. [PubMed]
38. Louis ED, Ottman R. Study of possible factors associated with age of onset in essential tremor. Mov Disord. 2006;21:1980–1986. [PubMed]
39. Louis ED, Dogu O. Does age of onset in essential tremor have a bimodal distribution? Data from a tertiary referral setting and a population-based study. Neuroepidemiology. 2007;29:208–212. [PMC free article] [PubMed]
40. Louis ED, Barnes LF, Ford B, Pullman SL, Yu Q. Ethnic differences in essential tremor. Arch Neurol. 2000;57:723–727. [PubMed]
41. Louis ED, Marder K, Cote L, Pullman S, Ford B, Wilder D, Tang MX, Lantigua R, Gurland B, Mayeux R. Differences in the prevalence of essential tremor among elderly African Americans, Whites, and Hispanics in Northern Manhattan, NY. Arch Neurol. 1995;52:1201–1205. [PubMed]
42. Louis ED, Fried LP, Fitzpatrick AL, Longstreth WT, Jr, Newman AB. Regional and racial differences in the prevalence of physician-diagnosed essential tremor in the United States. Mov Disord. 2003;18:1035–1040. [PubMed]
43. Rajput AH, Offord KP, Beard CM, Kurland LT. Essential tremor in Rochester, Minnesota: a 45-year study. J Neurol Neurosurg Psychiatry. 1984;47:466–470. [PMC free article] [PubMed]
44. Benito-Leon J, Bermejo-Pareja F, Louis ED. Incidence of essential tremor in three elderly populations of central Spain. Neurology. 2005;64:1721–1725. [PubMed]
45. Critchley M. Observations of essential (heredofamilial) tremor. Brain. 1949;72:113–139. [PubMed]
46. Louis ED, Ford B, Barnes LF. Clinical subtypes of essential tremor. Arch Neurol. 2000;57:1194–1198. [PubMed]
47. Louis ED, Jurewicz EC, Watner D. Community-based data on associations of disease duration and age with severity of essential tremor: implications for disease pathophysiology. Mov Disord. 2003;18:90–93. [PubMed]
48. Elble RJ, Higgins C, Hughes L. Longitudinal study of essential tremor. Neurology. 1992;42:441–443. [PubMed]
49. Putzke JD, Whaley NR, Baba Y, Wszolek ZK, Uitti RJ. Essential tremor: predictors of disease progression in a clinical cohort. J Neurol Neurosurg Psychiatry. 2006;77:1235–1237. [PMC free article] [PubMed]
50. Yahr MD, Orosz D, Purohit DP. Co-occurrence of essential tremor and Parkinson's disease: clinical study of a large kindred with autopsy findings. Parkinsonism Relat Disord. 2003;9:225–231. [PubMed]
51. Shahed J, Jankovic J. Exploring the relationship between essential tremor and Parkinson's disease. Parkinsonism Relat Disord. 2007;13:67–76. [PubMed]
52. Louis ED, Levy G, Mejia-Santana H, Cote L, Andrews H, Harris J, Waters C, Ford B, Frucht S, Fahn S, Ottman R, Marder K. Risk of action tremor in relatives of tremor-dominant and postural instability gait disorder PD. Neurology. 2003;61:931–936. [PubMed]
53. Ondo WG, Lai D. Olfaction testing in patients with tremor-dominant Parkinson's disease: Is this a distinct condition? Mov Disord. 2005;20:471–475. [PubMed]
54. Pahwa R, Koller WC. Is there a relationship between Parkinson's disease and essential tremor? Clin Neuropharmacol. 1993;16:30–35. [PubMed]
55. Geraghty JJ, Jankovic J, Zetusky WJ. Association between essential tremor and Parkinson's disease. Ann Neurol. 1985;17:329–333. [PubMed]
56. Chaudhuri KR, Buxton-Thomas M, Dhawan V, Peng R, Meilak C, Brooks DJ. Long duration asymmetrical postural tremor is likely to predict development of Parkinson's disease and not essential tremor: clinical follow up study of 13 cases. J Neurol Neurosurg Psychiatry. 2005;76:115–117. [PMC free article] [PubMed]
57. Louis ED, Frucht SJ. Prevalence of essential tremor in patients with Parkinson's disease versus Parkinson-plus syndromes. Mov Disord. 2007;22:1402–1407. [PubMed]
58. Benito-Leon J, Bermejo-Pareja F. Risk of incident Parkinson's disease and Parkinsonism in essential tremor: a population-based study. Neurology. 2008;70:A191.
59. Louis ED, Faust PL, Vonsattel JP, Honig LS, Rajput A, Robinson CA, Pahwa R, Lyons KE, Ross GW, Borden S, Moskowitz CB, Lawton A, Hernandez N. Neuropathological changes in essential tremor: 33 cases compared with 21 controls. Brain. 2007;130:3297–3307. [PubMed]
60. Louis ED, Honig LS, Vonsattel JP, Maraganore DM, Borden S, Moskowitz CB. Essential tremor associated with focal nonnigral Lewy bodies: a clinicopathologic study. Arch Neurol. 2005;62:1004–1007. [PubMed]
61. Ross GW, Cerosimo M, et al. Pathological investigation of essential tremor Neurology. 2004;62:A537–A538.
62. Louis ED, Benito-Leon J, Ottman R, Bermejo-Pareja F. A population-based study of mortality in essential tremor. Neurology. 2007;69:1982–1989. [PubMed]
63. Hardesty DE, Maraganore DM, Matsumoto JY, Louis ED. Increased risk of head tremor in women with essential tremor: longitudinal data from the Rochester Epidemiology Project. Mov Disord. 2004;19:529–533. [PubMed]
64. Louis ED, Ford B, Frucht S. Factors associated with increased risk of head tremor in essential tremor: a community-based study in Northern Manhattan. Mov Disord. 2003;18:432–436. [PubMed]
65. Hubble JP, Busenbark KL, Pahwa R, Lyons K, Koller WC. Clinical expression of essential tremor: effects of gender and age. Mov Disord. 1997;12:969–972. [PubMed]
66. Louis ED, Vonsattel JP. The emerging neuropathology of essential tremor. Mov Disord. 2007;23:174–182. [PMC free article] [PubMed]
67. Louis ED, Vonsattel JP, Honig LS, Ross GW, Lyons KE, Pahwa R. Neuropathologic findings in essential tremor. Neurology. 2006;66:1756–1759. [PubMed]
68. Higgins JJ, Lombardi RQ, Pucilowska J, Jankovic J, Golbe LI, Verhagen L. HS1-BP3 gene variant is common in familial essential tremor. Mov Disord. 2006;21:306–309. [PubMed]
69. Deng H, Le W, Jankovic J. Genetics of essential tremor. Brain. 2007;130:1456–1464. [PubMed]
70. Higgins JJ, Pho LT, Nee LE. A gene (ETM) for essential tremor maps to chromosome 2p22-p25. Mov Disord. 1997;12:859–864. [PubMed]
71. Higgins JJ, Loveless JM, Jankovic J, Patel PI. Evidence that a gene for essential tremor maps to chromosome 2p in four families. Mov Disord. 1998;13:972–977. [PubMed]
72. Kovach MJ, Ruiz J, Kimonis K, Mueed S, Sinha S, Higgins C, Elble S, Elble R, Kimonis VE. Genetic heterogeneity in autosomal dominant essential tremor. Genet Med. 2001;3:197–199. [PubMed]
73. Shatunov A, Sambuughin N, Jankovic J, Elble R, Lee HS, Singleton AB, Dagvadorj A, Ji J, Zhang Y, Kimonis VE, Hardy J, Hallett M, Goldfarb LG. Genomewide scans in North American families reveal genetic linkage of essential tremor to a region on chromosome 6p23. Brain. 2006;129:2318–2331. [PubMed]
74. Gulcher JR, Jonsson P, Kong A, Kristjansson K, Frigge ML, Karason A, Einarsdottir IE, Stefansson H, Einarsdottir AS, Sigurthoardottir S, Baldursson S, Bjornsdottir S, Hrafnkelsdottir SM, Jakobsson F, Benedickz J, Stefansson K. Mapping of a familial essential tremor gene, FET1, to chromosome 3q13. Nat Genet. 1997;17:84–87. [PubMed]
75. Marshall J. Observations on essential tremor. J Neurol Neurosurg Psychiatry. 1962;25:122–125. [PMC free article] [PubMed]
76. Higgins JJ, Jankovic J, Lombardi RQ, Pucilowska J, Tan EK, Ashizawa T, Ruszczyk MU. Haplotype analysis of the ETM2 locus in familial essential tremor. Neurogenetics. 2003;4:185–189. [PubMed]
77. Higgins JJ, Lombardi RQ, Pucilowska J, Jankovic J, Tan EK, Rooney JP. A variant in the HS1-BP3 gene is associated with familial essential tremor. Neurology. 2005;64:417–421. [PMC free article] [PubMed]
78. Higgins JJ, Lombardi RQ, Pucilowska J, Ruszczyk MU. Integrated physical map of the human essential tremor gene region (ETM2) on chromosome 2p24.3-p24.2. Am J Med Genet B Neuropsychiatr Genet. 2004;127:128–130. [PubMed]
79. Higgins JJ, Lombardi RQ, Tan EK, Jankovic J, Pucilowska J, Rooney JP. Haplotype analysis at the ETM2 locus in a Singaporean sample with familial essential tremor. Clin Genet. 2004;66:353–357. [PubMed]
80. Aridon P, Ragonese P, De Fusco M, Salemi G, Casari G, Savettieri G. Further evidence of genetic heterogeneity in familial essential tremor. Parkinsonism Relat Disord. 2007 [PubMed]
81. Ma S, Davis TL, Blair MA, Fang JY, Bradford Y, Haines JL, Hedera P. Familial essential tremor with apparent autosomal dominant inheritance: Should we also consider other inheritance modes? Mov Disord. 2006;21:1368–1374. [PubMed]
82. Martinez C, Garcia-Martin E, Alonso-Navarro H, Benito-Leon J, Puertas I, Rubio L, Lopez-Alburquerque T, Agundez JA, Jimenez-Jimenez FJ. Alcohol dehydrogenase 2 genotype and allelic variants are not associated with the risk for essential tremor. Clin Neuropharmacol. 2007;30:196–200. [PubMed]
83. Sazci A, Ergul E, Bayulkem K. Association of the c677t and a1298c polymorphisms of methylenetetrahydrofolate reductase gene in patients with essential tremor in turkey. Mov Disord. 2004;19:1472–1476. [PubMed]
84. Martinez C, Garcia-Martin E, Alonso-Navarro H, Benito-Leon J, Puertas I, Rubio L, Lopez-Alburquerque T, Agundez JA, Jimenez-Jimenez FJ. Glutathione-s-transferase p1 polymorphism and risk for essential tremor. Eur J Neurol. 2008;15:234–238. [PubMed]
85. Alonso-Navarro H, Martinez C, Garcia-Martin E, Benito-Leon J, Garcia-Ferrer I, Vazquez-Torres P, Puertas I, Lopez-Alburquerque T, Agundez JA, Jimenez-Jimenez FJ. Cyp2c19 polymorphism and risk for essential tremor. Eur Neurol. 2006;56:119–123. [PubMed]
86. Louis ED, Applegate L, Graziano JH, Parides M, Slavkovich V, Bhat HK. Interaction between blood lead concentration and δ-amino-levulinic acid dehydratase gene polymorphisms increases the odds of essential tremor. Mov Disord. 2005;20:1170–1177. [PubMed]
87. Blair MA, Ma S, Phibbs F, Fang JY, Cooper MK, Davis TL, Hedera P. Reappraisal of the role of the DRD3 gene in essential tremor. Parkinsonism Relat Disord. 2008 [PMC free article] [PubMed]
88. Deng H, Xie WJ, Le WD, Huang MS, Jankovic J. Genetic analysis of the GABRA1 gene in patients with essential tremor. Neurosci Lett. 2006;401:16–19. [PubMed]
89. Xiao Y, Zhang BS. Association of the polymorphism in α-2 macroglobulin gene with essential tremor and Parkinson's disease. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2006;23:84–85. [PubMed]
90. Agundez JA, Jimenez-Jimenez FJ, Tejeda R, Ledesma MC, Orti-Pareja M, Gasalla T, Molina JA, Ruiz J, Coria F, Duarte J, Vazquez A, Ladero JM, Benitez J. CYP2D6 polymorphism is not associated with essential tremor. Eur Neurol. 1997;38:99–104. [PubMed]
91. Louis ED, Ottman R. How familial is familial tremor? The genetic epidemiology of essential tremor. Neurology. 1996;46:1200–1205. [PubMed]
92. Louis ED, Ottman R, Ford B, Pullman S, Martinez M, Fahn S, Hauser WA. The Washington Heights-Inwood genetic study of essential tremor: methodologic issues in essential-tremor research. Neuroepidemiology. 1997;16:124–133. [PubMed]
93. Hornabrook RW, Nagurney JT. Essential tremor in Papua, New Guinea. Brain. 1976;99:659–672. [PubMed]
94. Critchley E. Clinical manifestations of essential tremor. J Neurol Neurosurg Psychiatry. 1972;35:365–372. [PMC free article] [PubMed]
95. Salemi G, Aridon P, Calagna G, Monte M, Savettieri G. Population-based case-control study of essential tremor. Ital J Neurol Sci. 1998;19:301–305. [PubMed]
96. Martinelli P, Gabellini AS, Gulli MR, Lugaresi E. Different clinical features of essential tremor: a 200-patient study. Acta Neurol Scand. 1987;75:106–111. [PubMed]
97. Aiyesimoju AB, Osuntokun BO, Bademosi O, Adeuja AO. Hereditary neurodegenerative disorders in Nigerian Africans. Neurology. 1984;34:361–362. [PubMed]
98. Tanner CM, Goldman SM, Lyons KE, Aston DA, Tetrud JW, Welsh MD, Langston JW, Koller WC. Essential tremor in twins: an assessment of genetic versus environmental determinants of etiology. Neurology. 2001;57:1389–1391. [PubMed]
99. Lorenz D, Frederiksen H, Moises H, Kopper F, Deuschl G, Christensen K. High concordance for essential tremor in monozygotic twins of old age. Neurology. 2004;62:208–211. [PubMed]
100. Larsson T, Sjogren T. Essential tremor: a clinical and genetic population study. Acta Psychiatr Scand Suppl. 1960;36:1–176. [PubMed]
101. Louis ED, Ford B, Frucht S, Barnes LF, X-Tang M, Ottman R. Risk of tremor and impairment from tremor in relatives of patients with essential tremor: a community-based family study. Ann Neurol. 2001;49:761–769. [PubMed]
102. Gorell JM, Johnson CC, Rybicki BA, Peterson EL, Kortsha GX, Brown GG, Richardson RJ. Occupational exposure to manganese, copper, lead, iron, mercury and zinc and the risk of Parkinson's disease. Neurotoxicology. 1999;20:239–247. [PubMed]
103. Gorell JM, Johnson CC, Rybicki BA, Peterson EL, Kortsha GX, Brown GG, Richardson RJ. Occupational exposures to metals as risk factors for Parkinson's disease. Neurology. 1997;48:650–658. [PubMed]
104. Gorell JM, Johnson CC, Rybicki BA, Peterson EL, Richardson RJ. The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living. Neurology. 1998;50:1346–1350. [PubMed]
105. Rybicki BA, Johnson CC, Uman J, Gorell JM. Parkinson's disease mortality and the industrial use of heavy metals in Michigan. Mov Disord. 1993;8:87–92. [PubMed]
106. Racette BA, McGee-Minnich L, Moerlein SM, Mink JW, Videen TO, Perlmutter JS. Welding-related Parkinsonism: clinical features, treatment, and pathophysiology. Neurology. 2001;56:8–13. [PubMed]
107. Baldereschi M, Inzitari M, Vanni P, Di Carlo A, Inzitari D. Pesticide exposure might be a strong risk factor for Parkinson's disease. Ann Neurol. 2007 [PubMed]
108. Dick FD. Parkinson's disease and pesticide exposures. Br Med Bull. 2006;79–80:219–231. [PubMed]
109. Ritz B, Yu F. Parkinson's disease mortality and pesticide exposure in California 1984–1994. Int J Epidemiol. 2000;29:323–329. [PubMed]
110. Semchuk KM, Love EJ, Lee RG. Parkinson's disease and exposure to agricultural work and pesticide chemicals. Neurology. 1992;42:1328–1335. [PubMed]
111. Shcherbatykh I, Carpenter DO. The role of metals in the etiology of Alzheimer's disease. J Alzheimers Dis. 2007;11:191–205. [PubMed]
112. Perl DP. Relationship of aluminum to Alzheimer's disease. Environ Health Perspect. 1985;63:149–153. [PMC free article] [PubMed]
113. Morahan JM, Yu B, Trent RJ, Pamphlett R. Genetic susceptibility to environmental toxicants in ALS. Am J Med Genet B Neuropsychiatr Genet. 2007;144:885–890. [PubMed]
114. Lambert D, Waters CH. Essential tremor. Curr Treat Options Neurol. 1999;1:6–13. [PubMed]
115. McKenna DJ. Plant hallucinogens: springboards for psychotherapeutic drug discovery. Behav Brain Res. 1996;73:109–116. [PubMed]
116. Zetler G, Singbartl G, Schlosser L. Cerebral pharmacokinetics of tremor-producing harmala and iboga alkaloids. Pharmacology. 1972;7:237–248. [PubMed]
117. Sakai S. Chemical studies of indole alkaloids. Yakugaku Zasshi. 1995;115:351–369. [PubMed]
118. De Meester C. Genotoxic potential of β-carbolines: a review. Mut Res. 1995;339:139–153. [PubMed]
119. Langston JW, Langston EB, Irwin I. MPTP-induced Parkinsonism in human and non-human primates – clinical and experimental aspects. Acta Neurol Scand Suppl. 1984;100:49–54. [PubMed]
120. Smeyne RJ, Jackson-Lewis V. The MPTP model of Parkinson's disease. Brain Res Mol Brain Res. 2005;134:57–66. [PubMed]
121. Du W, Aloyo VJ, Harvey JA. Harmaline competitively inhibits [3H]MK-801 binding to the nmda receptor in rabbit brain. Brain Res. 1997;770:26–29. [PubMed]
122. Martin FC, Handforth A. Carbenoxolone and mefloquine suppress tremor in the harmaline mouse model of essential tremor. Mov Disord. 2006;21:1641–1649. [PubMed]
123. Martin FC, Thu Le A, Handforth A. Harmaline-induced tremor as a potential preclinical screening method for essential tremor medications. Mov Disord. 2005;20:298–305. [PubMed]
124. Krahl SE, Martin FC, Handforth A. Vagus nerve stimulation inhibits harmaline-induced tremor. Brain Res. 2004;1011:135–138. [PubMed]
125. Handforth A, Krahl SE. Suppression of harmaline-induced tremor in rats by vagus nerve stimulation. Mov Disord. 2001;16:84–88. [PubMed]
126. Sinton CM, Krosser BI, Walton KD, Llinas RR. The effectiveness of different isomers of octanol as blockers of harmaline-induced tremor. Pflugers Arch. 1989;414:31–36. [PubMed]
127. Milner TE, Cadoret G, Lessard L, Smith AM. EMG analysis of harmaline-induced tremor in normal and three strains of mutant mice with Purkinje cell degeneration and the role of the inferior olive. J Neurophysiol. 1995;73:2568–2577. [PubMed]
128. Trouvin JH, Jacqmin P, Rouch C, Lesne M, Jacquot C. Benzodiazepine receptors are involved in tabernanthine-induced tremor: in vitro and in vivo evidence. Eur J Pharmacol. 1987;140:303–309. [PubMed]
129. Fuentes JA, Longo VG. An investigation on the central effects of harmine, harmaline and related β-carbolines. Neuropharmacology. 1971;10:15–23. [PubMed]
130. Cross AJ, Misra A, Sandilands A, Taylor MJ, Green AR. Effect of chlormethiazole, dizocilpine and pentobarbital on harmaline-induced increase of cerebellar cyclic GMP and tremor. Psychopharmacology (Berl) 1993;111:96–98. [PubMed]
131. Rappaport MS, Gentry RT, Schneider DR, Dole VP. Ethanol effects on harmaline-induced tremor and increase of cerebellar cyclic GMP. Life Sci. 1984;34:49–56. [PubMed]
132. Louis ED, Shungu DC, Chan S, Mao X, Jurewicz EC, Watner D. Metabolic abnormality in the cerebellum in patients with essential tremor: a proton magnetic resonance spectroscopic imaging study. Neurosci Lett. 2002;333:17–20. [PubMed]
133. Louis ED, Shungu DC, Mao X, Chan S, Jurewicz EC. Cerebellar metabolic symmetry in essential tremor studied with 1H magnetic resonance spectroscopic imaging: implications for disease pathology. Mov Disord. 2004;19:672–677. [PubMed]
134. Louis ED, Vonsattel JP, Honig LS, Lawton A, Moskowitz C, Ford B, Frucht S. Essential tremor associated with pathologic changes in the cerebellum. Arch Neurol. 2006;63:1189–1193. [PubMed]
135. Pagan FL, Butman JA, Dambrosia JM, Hallett M. Evaluation of essential tremor with multi-voxel magnetic resonance spectroscopy. Neurology. 2003;60:1344–1347. [PubMed]
136. Shill H, Sabbagh M, Connor D, Caviness J, Beach T. Pathological changes in prospectively-ascertained essential tremor subjects. Neurology. 2007;68
137. Axelrad JE LE, Honig LS, Flores I, Ross GW, Pahwa R, Lyons KE, Faust PL, Vonsattel JP. Reduced Purkinje cell number in essential tremor: a postmortem study. Arch Neurol. 2008;65:101–107. [PMC free article] [PubMed]
138. O'Hearn E, Long DB, Molliver ME. Ibogaine induces glial activation in parasagittal zones of the cerebellum. Neuroreport. 1993;4:299–302. [PubMed]
139. O'Hearn E, Molliver ME. Degeneration of purkinje cells in parasagittal zones of the cerebellar vermis after treatment with ibogaine or harmaline. Neuroscience. 1993;55:303–310. [PubMed]
140. O'Hearn E, Molliver ME. The olivocerebellar projection mediates ibogaine-induced degeneration of purkinje cells: a model of indirect, trans-synaptic excitotoxicity. J Neurosci. 1997;17:8828–8841. [PubMed]
141. Robertson HA. Harmaline-induced tremor: the benzodiazepine receptor as a site of action. Eur J Pharmacol. 1980;67:129–132. [PubMed]
142. Lewin L. Untersuchungen über Banisteria caapi sp. Arch Exp Pathol Pharmacol. 1928;129:133–149.
143. Pennes HH, Hoch PH. Psychotomimetics, clinical and theoretical considerations: harmine, win-2299 and nalline. Am J Psychiatry. 1957;113:887–892. [PubMed]
144. Moncrieff J. Determination of pharmacological levels of harmane, harmine and harmaline in mammalian brain tissue, cerebrospinal fluid and plasma by high-performance liquid chromatography with fluorimetric detection. J Chromatogr. 1989;496:269–278. [PubMed]
145. Anderson NJ, Tyacke RJ, Husbands SM, Nutt DJ, Hudson AL, Robinson ES. In vitro and ex vivo distribution of [3H]harmane, an endogenous β-carboline, in rat brain. Neuropharmacology. 2006;50:269–276. [PubMed]
146. Matsubara K, Collins MA, Akane A, Ikebuchi J, Neafsey EJ, Kagawa M, Shiono H. Potential bioactivated neurotoxicants, n-methylated β-carbolinium ions, are present in human brain. Brain Res. 1993;610:90–96. [PubMed]
147. Gearhart DA, Collins MA, Lee JM, Neafsey EJ. Increased β-carboline 9N-methyltransferase activity in the frontal cortex in Parkinson's disease. Neurobiol Dis. 2000;7:201–211. [PubMed]
148. Wakabayashi K, Totsuka Y, Fukutome K, Oguri A, Ushiyama H, Sugimura T. Human exposure to mutagenic/carcinogenic heterocyclic amines and comutagenic β-carbolines. Mutat Res. 1997;376:253–259. [PubMed]
149. Pfau W, Skog K. Exposure to β-carbolines norharman and harman. J Chromatogr B Analyt Technol Biomed Life Sci. 2004;802:115–126. [PubMed]
150. Gross GA, Turesky RJ, Fay LB, Stillwell WG, Skipper PL, Tannenbaum SR. Heterocyclic aromatic amine formation in grilled bacon, beef and fish and in grill scrapings. Carcinogenesis. 1993;14:2313–2318. [PubMed]
151. Skog K, Solyakov A, Arvidsson P, Jagerstad M. Analysis of nonpolar heterocyclic amines in cooked foods and meat extracts using gas chromatography-mass spectrometry. J Chromatogr A. 1998;803:227–233. [PubMed]
152. Skog K. Cooking procedures and food mutagens: a literature review. Food Chem Toxicol. 1993;31:655–675. [PubMed]
153. Layton DW, Bogen KT, Knize MG, Hatch FT, Johnson VM, Felton JS. Cancer risk of heterocyclic amines in cooked foods: an analysis and implications for research. Carcinogenesis. 1995;16:39–52. [PubMed]
154. Sinha R, Rothman N, Salmon CP, Knize MG, Brown ED, Swanson CA, Rhodes D, Rossi S, Felton JS, Levander OA. Heterocyclic amine content in beef cooked by different methods to varying degrees of doneness and gravy made from meat drippings. Food Chem Toxicol. 1998;36:279–287. [PubMed]
155. Sinha R, Knize MG, Salmon CP, Brown ED, Rhodes D, Felton JS, Levander OA, Rothman N. Heterocyclic amine content of pork products cooked by different methods and to varying degrees of doneness. Food Chem Toxicol. 1998;36:289–297. [PubMed]
156. Herraiz T. Relative exposure to β-carbolines norharman and harman from foods and tobacco smoke. Food Addit Contam. 2004;21:1041–1050. [PubMed]
157. Louis ED, Zheng W, Jurewicz EC, Watner D, Chen J, Factor-Litvak P, Parides M. Elevation of blood β-carboline alkaloids in essential tremor. Neurology. 2002;59:1940–1944. [PubMed]
158. Louis ED, Jiang W, Pellegrino KM, Rios E, Factor-Litvak P, Henchcliffe C, Zheng W. Elevated blood harmane (1-methyl-9H-pyrido[3,4-B]indole) concentrations in essential tremor. Neurotoxicology. 2008;29:294–300. [PMC free article] [PubMed]
159. Louis ED, Zheng W, Mao X, Shungu DC. Blood harmane is correlated with cerebellar metabolism in essential tremor: a pilot study. Neurology. 2007;69:515–520. [PubMed]
160. Louis ED, Zheng W, Applegate L, Shi L, Factor-Litvak P. Blood harmane concentrations and dietary protein consumption in essential tremor. Neurology. 2005;65:391–396. [PubMed]
161. Willett WC, Sampson L, Stampfer MJ, Rosner B, Bain C, Witschi J, Hennekens CH, Speizer FE. Reproducibility and validity of a semiquantitative food frequency questionnaire. Am J Epidemiol. 1985;122:51–65. [PubMed]
162. Louis ED, Keating GA, Bogen KT, Rios E, Pellegrino KM, Factor-Litvak P. Dietary epidemiology of essential tremor: meat consumption and meat cooking practices. Neuroepidemiology. 2008;30:161–166. [PMC free article] [PubMed]
163. Kuhn W, Muller T, Grosse H, Rommelspacher H. Plasma harman and norharman in Parkinson's disease. J Neural Transm Suppl. 1995;46:291–295. [PubMed]
164. Coulehan JL, Hirsch W, Brillman J, Sanandria J, Welty TK, Colaiaco P, Koros A, Lober A. Gasoline sniffing and lead toxicity in Navajo adolescents. Pediatrics. 1983;71:113–117. [PubMed]
165. Winegar DA, Levy BS, Andrews JS, Jr, Landrigan PJ, Scruton WH, Krause MJ. Chronic occupational exposure to lead: an evaluation of the health of smelter workers. J Occup Med. 1977;19:603–606. [PubMed]
166. Booze RM, Mactutus CF, Annau Z, Tilson HA. Neonatal triethyl lead neurotoxicity in rat pups: initial behavioral observations and quantification. Neurobehav Toxicol Teratol. 1983;5:367–375. [PubMed]
167. Goldings AS, Stewart RM. Organic lead encephalopathy: behavioral change and movement disorder following gasoline inhalation. J Clin Psychiatry. 1982;43:70–72. [PubMed]
168. Seshia SS, Rjani KR, Boeckx RL, Chow PN. The neurological manifestations of chronic inhalation of leaded gasoline. Dev Med Child Neurol. 1978;20:323–334. [PubMed]
169. Valpey R, Sumi SM, Copass MK, Goble GJ. Acute and chronic progressive encephalopathy due to gasoline sniffing. Neurology. 1978;28:507–510. [PubMed]
170. Young RS, Grzyb SE, Crismon L. Recurrent cerebellar dysfunction as related to chronic gasoline sniffing in an adolescent girl: lead poisoning from ‘leaded’ gasoline as an attendent complication. Clin Pediatr (Phila) 1977;16:706–708. [PubMed]
171. McConnell P, Berry M. The effects of postnatal lead exposure on purkinje cell dendritic development in the rat. Neuropathol Appl Neurobiol. 1979;5:115–132. [PubMed]
172. Walsh TJ, Tilson HA. Neurobehavioral toxicology of the organoleads. Neurotoxicology. 1984;5:67–86. [PubMed]
173. Louis ED, Jurewicz EC, Applegate L, Factor-Litvak P, Parides M, Andrews L, Slavkovich V, Graziano JH, Carroll S, Todd A. Association between essential tremor and blood lead concentration. Environ Health Perspect. 2003;111:1707–1711. [PMC free article] [PubMed]
174. Dogu O, Louis ED, Tamer L, Unal O, Yilmaz A, Kaleagasi H. Elevated blood lead concentrations in essential tremor: a case-control study in Mersin, Turkey. Environ Health Perspect. 2007;115:1564–1568. [PMC free article] [PubMed]
175. Taylor JR. Neurological manifestations in humans exposed to chlordecone and follow-up results. Neurotoxicology. 1982;3:9–16. [PubMed]
176. Taylor JR, Selhorst JB, Houff SA, Martinez AJ. Chlordecone intoxication in man. I. Clinical observations. Neurology. 1978;28:626–630. [PubMed]
177. Louis ED, Factor-Litvak P, Parides M, Andrews L, Santella RM, Wolff MS. Organochlorine pesticide exposure in essential tremor: a case-control study using biological and occupational exposure assessments. Neurotoxicology. 2006;27:579–586. [PubMed]
178. Cannon SB, Veazey JM, Jr, Jackson RS, Burse VW, Hayes C, Straub WE, Landrigan PJ, Liddle JA. Epidemic kepone poisoning in chemical workers. Am J Epidemiol. 1978;107:529–537. [PubMed]
179. Jiménez-Jiménez FJdT-HM, Alonso-Navarro H, Ayuso-Peralta L, Arévalo-Serrano J, Ballesteros-Barranco A, Puertas I, Jabbour-Wadih T, Barcenilla B. Environmental risk factors for essential tremor. Eur Neurol. 2007;58:106–113. [PubMed]
180. Prakash KM, Fook-Choong S, Yuen Y, Tan EK. Exploring the relationship between caffeine intake and essential tremor. J Neurol Sci. 2006;251:98–101. [PubMed]
181. Louis ED, Applegate LM, Factor-Litvak P, Parides MK, Andrews L. Essential tremor: occupational exposures to manganese and organic solvents. Neurology. 2004;63:2162–2164. [PubMed]
182. Fabrizio E, Vanacore N, Valente M, Rubino A, Meco G. High prevalence of extrapyramidal signs and symptoms in a group of Italian dental technicians. BMC Neurol. 2007;7:24. [PMC free article] [PubMed]
183. Louis ED, Ford B, Pullman S, Baron K. How normal is ‘normal’? Mild tremor in a multiethnic cohort of normal subjects. Arch Neurol. 1998;55:222–227. [PubMed]
184. Ben-Shlomo Y. How far are we in understanding the cause of parkinson's disease? J Neurol Neurosurg Psychiatry. 1996;61:4–16. [PMC free article] [PubMed]
185. Rautakorpi I, Marttila RJ, Rinne UK. Alcohol consumption of patients with essential tremor. Acta Neurol Scand. 1983;68:177–179. [PubMed]
186. Nasrallah HA, Schroeder D, Petty F. Alcoholism secondary to essential tremor. J Clin Psychiatry. 1982;43:163–164. [PubMed]
187. Louis ED, Jurewicz EC, Applegate L, Luchsinger JA, Factor-Litvak P, Parides M. Semiquantitative study of current coffee, caffeine, and ethanol intake in essential tremor cases and controls. Mov Disord. 2004;19:499–504. [PubMed]
188. Torvik A, Torp S. The prevalence of alcoholic cerebellar atrophy: a morphometric and histological study of an autopsy material. J Neurol Sci. 1986;75:43–51. [PubMed]
189. Gorell JM, Rybicki BA, Johnson CC, Peterson EL. Smoking and parkinson's disease: a dose-response relationship. Neurology. 1999;52:115–119. [PubMed]
190. Ritz B, Ascherio A, Checkoway H, Marder KS, Nelson LM, Rocca WA, Ross GW, Strickland D, Van Den Eeden SK, Gorell J. Pooled analysis of tobacco use and risk of Parkinson disease. Arch Neurol. 2007;64:990–997. [PubMed]
191. Benito-Leon J, Louis ED, Permejo-Pareja F. Population-based case-control study of cigarette smoking and essential tremor. Mov Disord. 2008;23:246–252. [PubMed]
192. Louis ED, Benito-Leon J, Permejo-Pareja F. Population-based prospective study of cigarette smoking and risk of incident essential tremor. Neurology. 2008;70:1682–1687. [PMC free article] [PubMed]
193. Mudo G, Belluardo N, Fuxe K. Nicotinic receptor agonists as neuroprotective/neurotrophic drugs: progress in molecular mechanisms. J Neural Transm. 2007;114:135–147. [PubMed]
194. Meissner W, Hill MP, Tison F, Gross CE, Bezard E. Neuroprotective strategies for Parkinson's disease: conceptual limits of animal models and clinical trials. Trends Pharmacol Sci. 2004;25:249–253. [PubMed]
195. Zanardi A, Leo G, Biagini G, Zoli M. Nicotine and neurodegeneration in ageing. Toxicol Lett. 2002;127:207–215. [PubMed]
196. Jeyarasasingam G, Tompkins L, Quik M. Stimulation of non-α7 nicotinic receptors partially protects dopaminergic neurons from 1-methyl-4-phenylpyridinium-induced toxicity in culture. Neuroscience. 2002;109:275–285. [PubMed]
197. Maggio R, Riva M, Vaglini F, Fornai F, Molteni R, Armogida M, Racagni G, Corsini GU. Nicotine prevents experimental parkinsonism in rodents and induces striatal increase of neurotrophic factors. J Neurochem. 1998;71:2439–2446. [PubMed]

Articles from Neuroepidemiology are provided here courtesy of Karger Publishers